Effects of lyophilized powder of spleen aminopeptide in treatment of children with mycoplasma pneumoniae pneumonia
Objective:To observe effects of lyophilized powder of spleen aminopeptide in treatment of children with mycoplasma pneumoniae pneumonia(MPP).Methods:The clinical data of 78 children with MPP admitted to the hospital from September 2022 to August 2023 were retrospectively analyzed.According to different treatment options,they were divided into control group and study group,39 cases in each group.The control group was treated with Azithromycin sequential therapy combined with Ambroxol,while the study group was treated with lyophilized powder of spleen aminopeptide orally on the basis of that of the control group before and after the treatment.The clinical efficacy,the disappearance time of clinical symptoms and signs,the levels of T cell subsets indexes(CD4+,CD4+/CD8+,CD3+)and inflammatory factors[granulocyte colony-stimulating factor(G-CSF),soluble intercellular adhesion molecule-1(sICAM-1),interleukin(IL)-12,IL-18].and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of treatment in the study group was 94.87%(37/39),which was higher than 76.92%(30/39)in the control group,and the difference was statistically significant(P<0.05).The disappearance time of clinical symptoms and signs such as fever,cough,pulmonary rales and asthma in the study group was shorter than that in the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of CD4+,CD4+/CD8+and CD3+in the two groups were higher than those before the treatment,those in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05).The levels of G-CSF,sICAM-1,IL-12 and IL-18 in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:On the basis of Azithromycin sequential therapy combined with Ambroxol treatment,spleen aminopeptide in the treatment of the children with MPP can improve the total effective rate of treatment and the T cell subsets levels,shorten the disappearance time of clinical symptoms and signs,and reduce the levels of inflammatory factors.Moreover,it is superior to single Azithromycin sequential therapy combined with Ambroxol treatment.